skip to main content
DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Selective Destruction Of Cells Infected With The Human Immunodeficiency Virus

Abstract

Compositions and methods for selectively killing a cell containing a viral protease are disclosed. The composition is a varient of a protein synthesis inactivating toxin wherein a viral protease cleavage site is interposed between the A and B chains. The variant of the type II ribosome-inactivating protein is activated by digestion of the viral protease cleavage site by the specific viral protease. The activated ribosome-inactivating protein then kills the cell by inactivating cellular ribosomes. A preferred embodiment of the invention is specific for human immunodeficiency virus (HIV) and uses ricin as the ribosome-inactivating protein. In another preferred embodiment of the invention, the variant of the ribosome-inactivating protein is modified by attachment of one or more hydrophobic agents. The hydrophobic agent facilitates entry of the variant of the ribosome-inactivating protein into cells and can lead to incorporation of the ribosome-inactivating protein into viral particles. Still another preferred embodiment of the invention includes a targeting moiety attached to the variants of the ribosome-inactivating protein to target the agent to HIV infectable cells.

Inventors:
 [1];  [1]
  1. Idaho Falls, ID
Issue Date:
Research Org.:
Idaho National Lab. (INL), Idaho Falls, ID (United States); BECHTEL BWXT IDAHO LLC
OSTI Identifier:
880117
Patent Number(s):
7018633
Application Number:
10/618560
Assignee:
Battelle Energy Alliance, LLC (Idaho Falls, ID)
Patent Classifications (CPCs):
A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Y - NEW / CROSS SECTIONAL TECHNOLOGIES Y10 - TECHNICAL SUBJECTS COVERED BY FORMER USPC Y10S - TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
DOE Contract Number:  
AC07-94ID13223; AC07-99ID13727; AC07-05ID14517
Resource Type:
Patent
Country of Publication:
United States
Language:
English

Citation Formats

Keener, William K, and Ward, Thomas E. Selective Destruction Of Cells Infected With The Human Immunodeficiency Virus. United States: N. p., 2006. Web.
Keener, William K, & Ward, Thomas E. Selective Destruction Of Cells Infected With The Human Immunodeficiency Virus. United States.
Keener, William K, and Ward, Thomas E. Tue . "Selective Destruction Of Cells Infected With The Human Immunodeficiency Virus". United States. https://www.osti.gov/servlets/purl/880117.
@article{osti_880117,
title = {Selective Destruction Of Cells Infected With The Human Immunodeficiency Virus},
author = {Keener, William K and Ward, Thomas E},
abstractNote = {Compositions and methods for selectively killing a cell containing a viral protease are disclosed. The composition is a varient of a protein synthesis inactivating toxin wherein a viral protease cleavage site is interposed between the A and B chains. The variant of the type II ribosome-inactivating protein is activated by digestion of the viral protease cleavage site by the specific viral protease. The activated ribosome-inactivating protein then kills the cell by inactivating cellular ribosomes. A preferred embodiment of the invention is specific for human immunodeficiency virus (HIV) and uses ricin as the ribosome-inactivating protein. In another preferred embodiment of the invention, the variant of the ribosome-inactivating protein is modified by attachment of one or more hydrophobic agents. The hydrophobic agent facilitates entry of the variant of the ribosome-inactivating protein into cells and can lead to incorporation of the ribosome-inactivating protein into viral particles. Still another preferred embodiment of the invention includes a targeting moiety attached to the variants of the ribosome-inactivating protein to target the agent to HIV infectable cells.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2006},
month = {3}
}

Patent:

Save / Share:

Works referenced in this record:

Primary Structure of Three Distinct Isoabrins Determined by cDNA Sequencing
journal, January 1993


Ricin: structure, mode of action, and some current applications.
journal, February 1994


Cloning and expression of three abrin A-chains and their mutants derived by site-specific mutagenesisin Escherichia coli
journal, January 1994


Bryodin, a single-chain ribosome-inactivating protein, selectively inhibits the growth of HIV-1-infected cells and reduces HIV-1 production
journal, December 1993


HIV-infected cells are killed by rCD4-ricin A chain
journal, November 1988


T-immunogenic peptides are constituted of rare sequence patterns. Use in the identification of T epitopes in the human immunodeficiency virus gag protein
journal, October 1988


Poxvirus pathogenesis.
journal, January 1991


Recombinant proricin binds galactose but does not depurinate 28 S ribosomal RNA
journal, September 1989


Genomic cloning and characterization of a ricin gene from Ricinus Communis
journal, January 1985


Regulation of Intracellular Human Immunodeficiency Virus Type-1 Protease Activity
journal, April 1998


Preparation and characterization of recombinant proricin containing an alternative protease-sensitive linker sequence
journal, September 1992


A microchemical facility for the analysis and synthesis of genes and proteins
journal, July 1984


Rationale for the Use of Immunotoxins in the Treatment of HIV-infected Humans
journal, January 1998


Crystal structure of the principal neutralization site of HIV-1
journal, April 1994